← Back to Screener
Amicus Therapeutics, Inc (FOLD)
Price$14.46
Favorite Metrics
Price vs S&P 500 (26W)65.47%
Price vs S&P 500 (4W)-9.29%
Market Capitalization$4.54B
All Metrics
P/CF (Annual)136.94x
Book Value / Share (Quarterly)$0.88
P/TBV (Annual)16.92x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)24.43%
Cash Flow / Share (Quarterly)$0.10
Price vs S&P 500 (YTD)-2.59%
Gross Margin (TTM)88.50%
Net Profit Margin (TTM)-4.27%
EPS (TTM)$-0.09
10-Day Avg Trading Volume2.85M
EPS Excl Extra (TTM)$-0.09
Revenue Growth (5Y)19.44%
EPS (Annual)$-0.09
ROI (Annual)-4.07%
Gross Margin (Annual)88.50%
Net Profit Margin (5Y Avg)-41.34%
Cash / Share (Quarterly)$0.94
Revenue Growth QoQ (YoY)23.72%
ROA (Last FY)-2.85%
Revenue Growth TTM (YoY)20.05%
EBITD / Share (TTM)$0.16
ROE (5Y Avg)-81.46%
Operating Margin (TTM)5.17%
Cash Flow / Share (Annual)$0.10
P/B Ratio16.55x
P/B Ratio (Quarterly)16.06x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)7.44x
Net Interest Coverage (TTM)1.00x
ROA (TTM)-3.17%
EPS Growth QoQ (YoY)-88.57%
EV / EBITDA (TTM)93.43x
EPS Incl Extra (Annual)$-0.09
Current Ratio (Annual)2.84x
Quick Ratio (Quarterly)1.72x
3-Month Avg Trading Volume8.46M
52-Week Price Return115.82%
EV / Free Cash Flow (Annual)158.05x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$0.84
P/S Ratio (Annual)7.16x
Asset Turnover (Annual)0.67x
52-Week High$14.48
Operating Margin (5Y Avg)-29.01%
EPS Excl Extra (Annual)$-0.09
CapEx CAGR (5Y)0.41%
Tangible BV CAGR (5Y)-0.23%
26-Week Price Return74.22%
Quick Ratio (Annual)1.72x
13-Week Price Return0.56%
Total Debt / Equity (Annual)1.43x
Current Ratio (Quarterly)2.84x
Enterprise Value$4,717.53
Revenue / Share Growth (5Y)15.34%
Asset Turnover (TTM)0.74x
Book Value / Share Growth (5Y)-4.19%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)0.42x
Pretax Margin (Annual)0.03%
Cash / Share (Annual)$0.94
3-Month Return Std Dev2.48%
Gross Margin (5Y Avg)89.22%
Net Income / Employee (TTM)$-0
ROE (Last FY)-9.89%
Net Interest Coverage (Annual)1.00x
EPS Basic Excl Extra (Annual)$-0.09
P/FCF (TTM)77.22x
Receivables Turnover (TTM)5.86x
EV / Free Cash Flow (TTM)158.05x
Total Debt / Equity (Quarterly)1.43x
EPS Incl Extra (TTM)$-0.09
Receivables Turnover (Annual)5.86x
ROI (TTM)-4.39%
P/S Ratio (TTM)7.16x
Pretax Margin (5Y Avg)-39.12%
Revenue / Share (Annual)$2.06
Tangible BV / Share (Annual)$0.84
Forward P/E40.54x
Price vs S&P 500 (52W)80.73%
Year-to-Date Return1.54%
5-Day Price Return0.00%
EPS Normalized (Annual)$-0.09
ROA (5Y Avg)-17.97%
Net Profit Margin (Annual)-4.27%
Month-to-Date Return0.00%
Cash Flow / Share (TTM)$-0.57
EBITD / Share (Annual)$0.16
Operating Margin (Annual)5.17%
LT Debt / Equity (Annual)1.43x
P/CF (TTM)136.94x
ROI (5Y Avg)-24.64%
LT Debt / Equity (Quarterly)1.43x
EPS Basic Excl Extra (TTM)$-0.09
P/TBV (Quarterly)16.92x
P/B Ratio (Annual)16.06x
Inventory Turnover (TTM)0.42x
Pretax Margin (TTM)0.03%
Book Value / Share (Annual)$0.88
Price vs S&P 500 (13W)-2.31%
Beta0.44x
P/FCF (Annual)152.06x
Revenue / Share (TTM)$2.05
ROE (TTM)-12.02%
52-Week Low$5.51
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.86
3.57
3.57
3.57
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
FOLDAmicus Therapeutics, Inc | 7.16x | 20.05% | 88.50% | — | $14.46 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Amicus Therapeutics develops precision medicines for rare genetic diseases. Its pipeline includes an oral treatment for Fabry disease, a clinical-stage therapy for Pompe disease, and a rare disease gene therapy platform. The company targets high-impact orphan diseases with limited treatment options.